Disappointment Over Immunotherapy in Mesothelioma Disappointment Over Immunotherapy in Mesothelioma
Despite achieving better response rates in the second-line treatment of malignant pleural mesothelioma, pembrolizumab did not improve survival over chemotherapy in a phase 3 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Asbestosis | Cancer & Oncology | Chemotherapy | Hematology | Immunotherapy | Mesothelioma